Hermetica Superfood Encyclopedia
The Short Answer
Achyranthes aspera contains phenolics, flavonoids, lupeol, oleanolic acid, and ursolic acid that modulate free radical scavenging and inhibit cholinesterase and glycolytic enzymes at measurable IC50 concentrations. Preclinical data demonstrates acetylcholinesterase inhibition at IC50 values of 0.55–0.82 mg/mL and α-glucosidase inhibition at IC50 0.80 mg/mL, though no human clinical trials have confirmed these effects in therapeutic settings.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordBhomaane Achyranthes aspera benefits
Bhomaane — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**: Terpenoids including lupeol (1
74%) and oleanolic acid (0.54% in roots) suppress pro-inflammatory pathways, supporting the Basotho traditional use of Bhomaane for pain and swelling management.
**Antioxidant Protection**: Total phenolic content reaching 28
86 mg GAE/g in infusions and flavonoid content up to 38.48 mg RE/g in dichloromethane extracts contribute to free radical scavenging, with methanolic extract IC50 of 135.8 µg/mL in DPPH assays.
**Glycaemic Enzyme Inhibition**: Extracts inhibit α-amylase (IC50 1
65–1.78 mg/mL) and α-glucosidase (IC50 0.80 mg/mL), suggesting a potential role in slowing postprandial glucose absorption consistent with antidiabetic traditional applications.
**Cholinesterase Inhibition**
Methanol and dichloromethane extracts inhibit acetylcholinesterase (IC50 0.55–0.82 mg/mL) and butyrylcholinesterase (IC50 0.53–0.55 mg/mL), pointing toward possible neuroprotective or cognitive-support activity under preclinical conditions.
**Antimicrobial Effects**
Terpenoids and flavonoids in leaf and seed extracts disrupt microbial cell membranes, with alkaloids, tannins, and glycosides present in high concentrations (graded +++) in methanolic and ethanolic extracts supporting historical use as a topical antibiotic.
**Tyrosinase Inhibition**: An IC50 of 1
90 mg/mL for tyrosinase inhibition suggests potential skin-brightening or melanogenesis-modulating effects, a less commonly studied but emerging area for this plant's bioactive phenolic constituents.
**Hepatoprotective and Antiparasitic Potential**: Squalene (0
55%) and fatty acid constituents such as 9,12-octadecadienoic acid (1.12%), identified by GC-MS, contribute to cell membrane stabilisation and have been associated in broader literature with liver-protective and antiparasitic bioactivities.
Origin & History
Natural habitat
Achyranthes aspera is a pantropical weed native to Africa, Asia, and Australia, growing abundantly in disturbed soils, roadsides, and grasslands from sea level to moderate altitudes. In Lesotho and surrounding southern African nations, it thrives in highland savanna environments and is harvested from wild populations rather than cultivated. The plant is particularly prominent in the ethnobotanical traditions of Basotho communities, where it is known locally as Bhomaane and used for pain and inflammatory conditions.
“Achyranthes aspera has a multi-millennial history of medicinal use across African and Asian traditional medicine systems, appearing in Ayurvedic texts as 'Apamarga' and in Unani medicine for conditions including asthma, skin boils, snakebites, renal disorders, and fever. In Lesotho, the plant is known as Bhomaane and holds a distinct role in Basotho healing traditions, particularly for the management of musculoskeletal pain and inflammatory conditions, where healers prepare root and leaf decoctions for both internal consumption and topical application. Across sub-Saharan Africa, the plant's weedy ubiquity — thriving in disturbed soils and human settlements — made it a reliable and accessible therapeutic resource for rural communities without access to formal healthcare. Historical references in Ayurvedic pharmacopoeia describe the ash of the plant (known as Apamarga Kshara) as a digestive and detoxifying agent, illustrating the cross-cultural recognition of this species as pharmacologically significant across two major traditional medicine traditions.”Traditional Medicine
Scientific Research
The current evidence base for Achyranthes aspera consists entirely of in vitro enzyme inhibition studies and phytochemical characterisation analyses, with no published randomised controlled trials or structured human clinical studies identified as of the most recent literature review. Preclinical data includes UHPLC-HRMS profiling confirming flavonoid, phenol, and fatty acid abundance, alongside quantified IC50 values for cholinesterase, α-amylase, α-glucosidase, and tyrosinase inhibition across multiple extract polarities. TLC isolation, GC-MS whole-plant profiling, and methanolic extraction studies have consistently identified the same core bioactive constituents across geographically distinct samples, lending some reproducibility to phytochemical findings. The overall evidence quality is preliminary; while mechanistic plausibility is established at the cellular level, translation to human therapeutic outcomes remains unvalidated and extrapolation from in vitro IC50 data to clinical dosing is not scientifically justified without pharmacokinetic and clinical trial data.
Preparation & Dosage
Traditional preparation
**Traditional Infusion (Lesotho/Basotho practice)**
Aerial parts or roots are decocted in water; specific volumes and concentrations are community-transmitted and not standardised in published sources.
**Methanolic Extract (Research standard)**
3 mg/mL in in vitro efficacy studies; human-equivalent dosing has not been established or validated
Used at .
**Ethanolic Extract**
Seeds and leaves macerated in ethanol yield alkaloids, glycosides, and tannins graded +++ in qualitative assays; no standardised human dose available.
**Dichloromethane Extract**
48 mg RE/g) and demonstrates strongest cholinesterase inhibition in preclinical assays; not available in commercial supplement form
Rich in flavonoids (TFC 38..
**Whole Plant Hydroalcoholic Extract**
Profiled by GC-MS for fatty acids and terpenoids including squalene and lupeol; preparation method involves hydroalcoholic maceration but human dosing is undefined.
**Standardisation**
No commercial standardisation percentages for any active compound have been established; oleanolic acid (0.54% in roots) and lupeol (1.74%) represent potential marker compounds for future standardisation frameworks.
**Timing**
Traditional use is typically acute or episodic (applied for active pain or infection); no chronic supplementation protocols are documented.
Nutritional Profile
Achyranthes aspera is not primarily a nutritional food source but contains pharmacologically relevant phytochemicals at measurable concentrations: total phenolics up to 28.86 mg GAE/g (infusion), total flavonoids up to 38.48 mg RE/g (dichloromethane extract), and fatty acids including the polyunsaturated 9,12-octadecadienoic acid (linoleic acid, 1.12%) and squalene (0.55%) identified by GC-MS. Triterpenoids including lupeol (1.74%), oleanolic acid (0.54% in roots), and ursolic acid are present in root fractions, along with ferulic acid and caffeic acid detectable by TLC (Rf values 0.19–0.74). Alkaloids, tannins, glycosides, and steroids are present in moderate-to-high concentrations (++ to +++) in seed and leaf methanolic extracts. Bioavailability of these compounds from traditional aqueous preparations is likely lower than from optimised solvent extracts, and no human pharmacokinetic data on absorption, distribution, metabolism, or excretion currently exists for this species.
How It Works
Mechanism of Action
The primary anti-inflammatory and antioxidant actions of Achyranthes aspera are driven by polyphenols and triterpenoids — specifically ferulic acid, caffeic acid, ursolic acid, lupeol, and oleanolic acid — which scavenge reactive oxygen species, chelate metal ions, and suppress NF-κB-mediated inflammatory signalling pathways. Cholinesterase inhibition by methanol and dichloromethane fractions (AChE IC50 0.55–0.82 mg/mL; BChE IC50 0.53–0.55 mg/mL) suggests competitive or mixed inhibition at the enzyme's active site, a mechanism confirmed through network pharmacology modelling linking polyphenol-rich fractions to neurotherapeutic target nodes. Glycaemic control is mechanistically attributed to α-amylase and α-glucosidase inhibition — reducing the rate of starch hydrolysis and intestinal glucose absorption — with inhibitory potency comparable to moderate synthetic inhibitors at equivalent concentrations. Antimicrobial activity proceeds through disruption of bacterial and fungal cell membrane integrity by terpenoids and flavonoids, supported by the presence of tannins which precipitate microbial surface proteins and impair cell wall biosynthesis.
Clinical Evidence
No human clinical trials studying Achyranthes aspera for pain, inflammation, antidiabetic effects, or any other indication have been identified in the published literature. All quantified outcome data originates from in vitro enzyme assays (IC50 measurements) and phytochemical analyses rather than randomised or observational human studies. Confidence in the therapeutic efficacy of Bhomaane for its traditional indications — pain and inflammation in Lesotho ethnomedicine — rests exclusively on mechanistic plausibility derived from preclinical data and centuries of empirical traditional use. Conducting phase I safety trials and dose-escalation studies in human populations would be the necessary next step before any clinical claims can be substantiated.
Safety & Interactions
Formal toxicology studies for Achyranthes aspera in humans are absent from the published literature, and no maximum safe dose, NOAEL, or tolerable upper intake level has been established for any extract or preparation. The high phenolic content (up to 28.86 mg GAE/g) may cause gastrointestinal irritation, nausea, or mucosal discomfort at excessive intake, though no quantified threshold for these effects has been reported. Preclinical cholinesterase inhibition (AChE/BChE IC50 0.53–0.82 mg/mL) raises a theoretical drug interaction concern with pharmaceutical cholinesterase inhibitors used in Alzheimer's disease management (e.g., donepezil, rivastigmine), as additive inhibition could potentiate cholinergic side effects; similarly, α-glucosidase inhibition warrants caution in individuals taking antidiabetic medications such as acarbose or metformin. Use during pregnancy and lactation is not supported by safety data and should be avoided until human studies establish a safety profile; individuals with known hypersensitivity to Amaranthaceae family plants should also exercise caution.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Achyranthes asperaApamargaPrickly Chaff FlowerDevil's HorsewhipBhomaaneChirchita
Frequently Asked Questions
What is Bhomaane used for in Lesotho traditional medicine?
In Lesotho, Bhomaane (Achyranthes aspera) is traditionally used by Basotho healers to manage pain and inflammatory conditions, with roots and leaves prepared as decoctions for both oral consumption and topical application. The plant's triterpenoids — particularly lupeol (1.74%) and oleanolic acid (0.54% in roots) — are the bioactive compounds most strongly associated with its anti-inflammatory activity in preclinical research.
Does Achyranthes aspera have any proven anti-diabetic effects?
Preclinical in vitro studies show that Achyranthes aspera extracts inhibit α-amylase (IC50 1.65–1.78 mg/mL) and α-glucosidase (IC50 0.80 mg/mL), enzymes responsible for carbohydrate digestion and glucose absorption, suggesting a theoretical antidiabetic mechanism. However, no human clinical trials have tested these effects in diabetic patients, so the antidiabetic benefit has not been confirmed at a clinical level and should not replace prescribed diabetes management.
Is Bhomaane safe to take with prescription medications?
Bhomaane extracts show measurable cholinesterase inhibition in laboratory studies (AChE IC50 0.55–0.82 mg/mL), which raises a theoretical risk of interaction with pharmaceutical cholinesterase inhibitors like donepezil or rivastigmine used in Alzheimer's treatment. Additionally, its α-glucosidase inhibition may interact additively with antidiabetic drugs such as acarbose or metformin; anyone taking these medication classes should consult a healthcare provider before using Achyranthes aspera preparations.
What are the main bioactive compounds in Achyranthes aspera?
The primary bioactive compounds identified by UHPLC-HRMS and GC-MS analysis include the triterpenoids lupeol (1.74%), oleanolic acid (0.54%), and ursolic acid; phenolic acids ferulic acid and caffeic acid; the polyunsaturated fatty acid 9,12-octadecadienoic acid (1.12%); and the triterpene hydrocarbon squalene (0.55%). Total flavonoid content reaches 38.48 mg RE/g in dichloromethane extracts and total phenolics up to 28.86 mg GAE/g in aqueous infusions, with alkaloids, tannins, and glycosides also present in high concentrations.
What is the recommended dose of Achyranthes aspera supplement?
No standardised supplemental dose for Achyranthes aspera has been established in human clinical trials, as all published efficacy data comes from in vitro studies using concentrations around 3 mg/mL for enzyme inhibition assays. Traditional Basotho preparations rely on community-transmitted decoction methods without defined dose quantities, and no commercial supplement standardisation exists; until human pharmacokinetic and safety studies are completed, a safe and effective human dose cannot be recommended.
How does the anti-inflammatory activity of Bhomaane compare to other traditional pain-relief herbs?
Achyranthes aspera contains lupeol (1.74%) and oleanolic acid (0.54% in roots), which suppress pro-inflammatory pathways similarly to other traditional remedies like turmeric and ginger. Clinical evidence specifically supporting Bhomaane's anti-inflammatory mechanism is more limited than well-studied alternatives, though traditional Basotho medicine has long utilized it for pain and swelling management. The strength of its effects may depend on extraction method and concentration of active terpenoids.
Which extraction form of Achyranthes aspera provides the highest antioxidant content?
Dichloromethane extracts of Achyranthes aspera contain the highest flavonoid content at up to 38.48 mg RE/g, while water-based infusions deliver substantial phenolic compounds at 28.86 mg GAE/g. Alcohol-based extracts typically fall between these two forms in terms of antioxidant yield. The choice between forms depends on balancing maximum antioxidant potency against practical preparation and absorption considerations.
Is Bhomaane suitable for individuals with chronic inflammatory conditions like arthritis?
Achyranthes aspera may benefit those with inflammatory conditions due to its terpenoid content that suppresses pro-inflammatory pathways, aligning with historical Basotho use for swelling and pain. However, individual responses vary, and clinical evidence specific to arthritis is limited compared to established anti-inflammatory treatments. Anyone with chronic inflammatory conditions should consult a healthcare provider before adding Bhomaane to their regimen, particularly if taking immunomodulatory medications.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bhomaane-achyranthes-aspera curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
